Celldex Therapeutics, Inc. (CLDX) Expected to Post Quarterly Sales of $1.91 Million

Equities research analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to announce sales of $1.91 million for the current quarter, according to Zacks. Two analysts have provided estimates for Celldex Therapeutics’ earnings. The highest sales estimate is $2.11 million and the lowest is $1.70 million. Celldex Therapeutics posted sales of $1.87 million in the same quarter last year, which suggests a positive year over year growth rate of 2.1%. The business is expected to issue its next quarterly earnings results on Tuesday, March 13th.

On average, analysts expect that Celldex Therapeutics will report full year sales of $1.91 million for the current financial year, with estimates ranging from $9.30 million to $11.40 million. For the next financial year, analysts anticipate that the firm will report sales of $13.57 million per share, with estimates ranging from $100,000.00 to $34.10 million. Zacks’ sales averages are an average based on a survey of analysts that cover Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.07. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.93% and a negative net margin of 671.84%. The business’s revenue for the quarter was up 77.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) earnings per share.

Several equities analysts have recently commented on the company. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. WBB Securities restated a “buy” rating and set a $10.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Finally, HC Wainwright restated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, November 7th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $7.05.

A number of institutional investors and hedge funds have recently bought and sold shares of CLDX. Vanguard Group Inc. grew its stake in Celldex Therapeutics by 7.8% in the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock valued at $24,143,000 after purchasing an additional 708,095 shares during the last quarter. Meditor Group Ltd grew its stake in Celldex Therapeutics by 8.8% in the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock valued at $18,054,000 after purchasing an additional 512,700 shares during the last quarter. Ameriprise Financial Inc. purchased a new position in Celldex Therapeutics in the second quarter valued at about $943,000. Dimensional Fund Advisors LP grew its stake in Celldex Therapeutics by 69.0% in the second quarter. Dimensional Fund Advisors LP now owns 832,186 shares of the biopharmaceutical company’s stock valued at $2,056,000 after purchasing an additional 339,639 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Celldex Therapeutics by 741.9% in the third quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 310,638 shares during the last quarter. Institutional investors own 52.46% of the company’s stock.

Celldex Therapeutics (NASDAQ:CLDX) opened at $2.84 on Monday. The company has a market capitalization of $386.20, a price-to-earnings ratio of -2.81 and a beta of 2.73. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $3.94.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/29/celldex-therapeutics-inc-cldx-expected-to-post-quarterly-sales-of-1-91-million.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply